Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
MRKR Marker Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: MRKR
Price (delayed)
$1.11
Market cap
$12.56M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.33
Enterprise value
-$1.13M
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy
Highlights
Marker Therapeutics's quick ratio has increased by 13% YoY and by 3.9% from the previous quarter
Marker Therapeutics's gross profit has surged by 72% YoY but it has decreased by 14% QoQ
MRKR's revenue has surged by 72% year-on-year but it is down by 14% since the previous quarter
MRKR's net income has dropped by 126% year-on-year and by 19% since the previous quarter
The EPS has dropped by 108% year-on-year and by 12% since the previous quarter
Key stats
What are the main financial stats of MRKR
Market
Valuations
Earnings
Shares outstanding
11.31M
Market cap
$12.56M
Enterprise value
-$1.13M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.82
Price to sales (P/S)
2.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.2
Revenue
$5.7M
Gross profit
$5.7M
Operating income
-$13.18M
Net income
-$12.78M
EBIT
-$12.73M
EBITDA
-$12.73M
Free cash flow
-$12.57M
Per share
Balance sheet
Liquidity
EPS
-$1.33
EPS diluted
-$1.33
Free cash flow per share
-$1.13
Book value per share
$1.35
Revenue per share
$0.51
TBVPS
$1.53
Total assets
$16.99M
Total liabilities
$2.5M
Debt
$0
Equity
$14.49M
Working capital
$14.49M
Debt to equity
0
Current ratio
6.79
Quick ratio
6.46
Net debt/EBITDA
1.08
Margins
Efficiency
Dividend
EBITDA margin
-223.6%
Gross margin
100%
Net margin
-224.4%
Operating margin
-231.4%
Return on assets
-83%
Return on equity
-101.9%
Return on invested capital
-9,855.8%
Return on capital employed
-87.9%
Return on sales
-223.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MRKR stock price
How has the Marker Therapeutics stock price performed over time
Intraday
-1.77%
1 week
-4.31%
1 month
2.78%
1 year
-72.93%
YTD
-64.31%
QTD
-9.76%
Financial performance
How have Marker Therapeutics's revenue and profit performed over time
Revenue
$5.7M
Gross profit
$5.7M
Operating income
-$13.18M
Net income
-$12.78M
Gross margin
100%
Net margin
-224.4%
MRKR's net income has dropped by 126% year-on-year and by 19% since the previous quarter
Marker Therapeutics's gross profit has surged by 72% YoY but it has decreased by 14% QoQ
MRKR's revenue has surged by 72% year-on-year but it is down by 14% since the previous quarter
MRKR's operating margin is up by 40% year-on-year but it is down by 37% since the previous quarter
Price vs fundamentals
How does MRKR's price correlate with its fundamentals
Growth
What is Marker Therapeutics's growth rate over time
Valuation
What is Marker Therapeutics stock price valuation
P/E
N/A
P/B
0.82
P/S
2.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.2
The EPS has dropped by 108% year-on-year and by 12% since the previous quarter
The P/B is 70% below the last 4 quarters average of 2.7 and 63% below the 5-year quarterly average of 2.2
Marker Therapeutics's equity has increased by 23% YoY but it has decreased by 22% from the previous quarter
MRKR's P/S is 95% below its 5-year quarterly average of 46.3 and 65% below its last 4 quarters average of 6.1
MRKR's revenue has surged by 72% year-on-year but it is down by 14% since the previous quarter
Efficiency
How efficient is Marker Therapeutics business performance
The ROE has dropped by 177% year-on-year and by 13% since the previous quarter
The ROA has plunged by 166% YoY and by 14% from the previous quarter
The company's return on invested capital has surged by 58% QoQ
The ROS is down by 38% since the previous quarter and by 31% year-on-year
Dividends
What is MRKR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MRKR.
Financial health
How did Marker Therapeutics financials performed over time
MRKR's total liabilities is down by 28% since the previous quarter but it is up by 9% year-on-year
The total assets has contracted by 23% from the previous quarter but it has grown by 21% YoY
The company's debt is 100% lower than its equity
Marker Therapeutics's equity has increased by 23% YoY but it has decreased by 22% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.